Salwa Rahman

Salwa Rahman

Auto-generated profile, based on publicly available information

Salwa Rahman

Division of Cardiology, Advanced Cardiac Care, Columbia University Irving Medical Center, New York, NY

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 February 2024 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AVAndrea Fernandez Valledor
Andrea Fernandez Valledor
GRGal Rubinstein
Gal Rubinstein
CMCathrine M. Moeller
Cathrine M. Moeller
DLDaniel Lorenzatti
Daniel Lorenzatti
SRSalwa Rahman
Salwa Rahman
NUNir Uriel
Nir Uriel

1 November 2025 in Circulation: Heart Failure
Verified
Journal Article
Closed access
CMCathrine M. Moeller
Cathrine M. Moeller
AVAndrea Fernandez Valledor
Andrea Fernandez Valledor
DODaniel Oren
Daniel Oren
SRSalwa Rahman
Salwa Rahman
JBJulia Baranowska
Julia Baranowska
NUNir Uriel
Nir Uriel
BACKGROUND: The purpose of the current study was to investigate the clinical implications of elevated donor-derived cell-free DNA (dd-cfDNA) levels in heart transplantation recipients without evidence of rejection observed on endomyocardial biopsy. METHODS: We retrospectively analyzed dd-cfDNA samples from all consecutive heart transplantation recipients between 2019 and 2023, excluding those with multiorgan transplants. Each sample was paired with an endomyocardial biopsy (0. Elevated dd-cfDNA was defined as ≥0.12%, with a subanalysis using a threshold of 0.20%. Graft dysfunction was defined as an ejection fraction<50%. We excluded dd-cfDNA samples with concurrent histologically positive biopsy results, focusing on those with positive dd-cfDNA and negative biopsy findings. A mixed model Cox regression approach was applied to assess for mortality and graft dysfunction. RESULTS: Of 643 dd-cfDNA samples from 227 patients, 238 samples (37%) from 110 patients showed positive dd-cfDNA results with negative endomyocardial biopsy. The median age was 56 years, with 27% females and 53% White patients. The median time from heart transplantation to sample collection was 5 months (interquartile range, 3–12). Among the positive samples, the median dd-cfDNA level was 0.24% (interquartile range, 0.16%–0.53%) with 63% exceeding 0.20%. A higher prevalence of prior treated antibody-mediated rejection was observed in the dd-cfDNA positive group (15% versus 5%; P =0.002). Patients with elevated dd-cfDNA results ≥ 0.20% demonstrated a near 5-fold increased risk of mortality (hazard ratio, 4.6 [95% CI, 1.6–13.4]; P =0.005) and a 3-fold risk of graft dysfunction (hazard ratio, 3.4 [95% CI, 1.0–11.9]; P =0.054) compared with those with negative dd-cfDNA. CONCLUSIONS: In our cohort, patients with positive dd-cfDNA levels and negative biopsy results had higher rates of adverse outcomes, including graft dysfunction and mortality.

13 May 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
AVAndrea Fernandez Valledor
Andrea Fernandez Valledor
CMCathrine M. Moeller
Cathrine M. Moeller
DODaniel Oren
Daniel Oren
JBJulia Baranowska
Julia Baranowska
SRSalwa Rahman
Salwa Rahman
NUNir Uriel
Nir Uriel

28 May 2025 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
JBJulia Baranowska
Julia Baranowska
DODaniel Oren
Daniel Oren
AVAndrea Fernandez Valledor
Andrea Fernandez Valledor
MUMatan Uriel
Matan Uriel
CLChanghee Lee
Changhee Lee
NUNir Uriel
Nir Uriel

12 May 2023 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
KGKursat Gurel
Kursat Gurel
FKFarid Khasiyev
Farid Khasiyev
ASAntonio Spagnolo-Allende
Antonio Spagnolo-Allende
SRSalwa Rahman
Salwa Rahman
MLMinghua Liu
Minghua Liu
JGJose Gutierrez
Jose Gutierrez

23 January 2024 in Neurology
Verified
Journal Article
Closed access
DRDavid J. Roh
David J. Roh
RMRicardo Murguia-Fuentes
Ricardo Murguia-Fuentes
KGKürşat Gürel
Kürşat Gürel
FKFarid Khasiyev
Farid Khasiyev
SRSalwa Rahman
Salwa Rahman
JGJose Gutierrez
Jose Gutierrez
Red blood cell (RBC) concentrations are known to associate with ischemic stroke. It is unclear whether RBC concentrations associate specifically with small vessel disease lacunar infarcts. We investigated the hypothesis that RBC concentrations associate with both chronic covert and acute symptomatic brain MRI lacunar infarcts. A cross-sectional observational analysis was performed across 2 cohorts with available hematocrit (as the assessment of RBC concentration exposure) and MRI outcome data. The primary setting was a population-based cohort of stroke-free, older adult (>50 years) participants from the Northern Manhattan Study (NOMAS) enrolled between 2003 and 2009. A second replication sample consisted of patients admitted with acute stroke and enrolled into the Columbia Stroke Registry (CSR) between 2005 and 2020. Associations of hematocrit with (1) chronic, covert lacunar infarcts and (2) symptomatic (i.e., acute) lacunar strokes were separately assessed from the NOMAS and CSR cohorts, respectively, using general additive models after adjusting for relevant covariates. Of 1,218 NOMAS participants analyzed, 6% had chronic, covert lacunar infarcts. The association between hematocrit and these covert lacunar infarcts was U-shaped (χ2 = 9.21 for nonlinear associations; p = 0.03), with people with hematocrit extremes being more likely to have covert lacunar infarcts. Of the 1,489 CSR patients analyzed, 23% had acute lacunar strokes. In this sample, only the relationships of increased hematocrit concentrations and lacunar strokes were replicated (adjusted coefficient β = 0.020; SE = 0.009; p = 0.03). We identified relationships of hematocrit with MRI lacunar infarcts in both stroke-free and ischemic stroke cohorts, respectively. The relationship between increased hematocrit concentrations with lacunar infarcts was replicated in both cohorts. Further studies are required to clarify the mechanisms behind the relationships of hematocrit with ischemic cerebral small vessel disease.